Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Document first published:
Page updated:
Topic:
Publication type:

Arsenic trioxide in combination with all-trans retinoic acid (ATRA) is recommended to be available as a routine commissioning treatment option for high-risk acute promyelocytic leukaemia (APML) within the criteria set out in this document.

Document

Commissioning policy: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Commissioning policy: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 235 KB
  • 12 pages

Summary

Published 27 February 2025.

Document

Equality and Health Inequalities Impact Assessment (EHIA): Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Equality and Health Inequalities Impact Assessment (EHIA): Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 218 KB
  • 14 pages

Summary

Published 27 February 2025.

Document

Engagement report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Engagement report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 127 KB
  • 3 pages

Summary

Published 27 February 2025.

Document

Clinical panel report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Clinical panel report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 109 KB
  • 3 pages

Summary

Published 27 February 2025.

Document

Clinical Priorities Advisory Group summary report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Clinical Priorities Advisory Group summary report: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 253 KB
  • 12 pages

Summary

Published 27 February 2025.

Document

Evidence review: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Evidence review: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 822 KB
  • 59 pages

Summary

Published 27 February 2025.

Document

Public health evidence review: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

Public health evidence review: Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)

  • PDF
  • 96 KB
  • 2 pages